Figure 3 | Scientific Reports

Figure 3

From: Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

Figure 3

Forest plot of overall survival in NFF vs. S-1 subgroups (A), and NFF vs. FOLFIRINOX subgroups (B). NFF nanoliposomal irinotecan with fluorouracil and folinic acid, HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, CRP C–reactive protein, CA19-9 carbohydrate antigen 19-9, TTNT time to next treatment.

Back to article page